JP2009536156A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536156A5 JP2009536156A5 JP2009505499A JP2009505499A JP2009536156A5 JP 2009536156 A5 JP2009536156 A5 JP 2009536156A5 JP 2009505499 A JP2009505499 A JP 2009505499A JP 2009505499 A JP2009505499 A JP 2009505499A JP 2009536156 A5 JP2009536156 A5 JP 2009536156A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- formula
- hydrogen
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 C*N(*)C(C)=O Chemical compound C*N(*)C(C)=O 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79216206P | 2006-04-14 | 2006-04-14 | |
| PCT/US2007/009138 WO2007120827A2 (en) | 2006-04-14 | 2007-04-12 | Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009536156A JP2009536156A (ja) | 2009-10-08 |
| JP2009536156A5 true JP2009536156A5 (enExample) | 2011-05-26 |
Family
ID=38474269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009505499A Withdrawn JP2009536156A (ja) | 2006-04-14 | 2007-04-12 | ヘッジホッグ経路関連障害の処置におけるビアリールカルボキサミドの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090306149A1 (enExample) |
| EP (1) | EP2010170A2 (enExample) |
| JP (1) | JP2009536156A (enExample) |
| KR (1) | KR20090006089A (enExample) |
| CN (1) | CN101420949A (enExample) |
| AU (1) | AU2007238676A1 (enExample) |
| BR (1) | BRPI0710723A2 (enExample) |
| CA (1) | CA2648196A1 (enExample) |
| MX (1) | MX2008013204A (enExample) |
| RU (1) | RU2008144805A (enExample) |
| WO (1) | WO2007120827A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| WO2009086451A1 (en) | 2007-12-27 | 2009-07-09 | Infinity Pharmaceuticals, Inc. | Methods for stereoselective reduction |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| CN102015705B (zh) * | 2008-02-26 | 2013-11-13 | 武田药品工业株式会社 | 稠合的杂环衍生物及其用途 |
| JP5816087B2 (ja) * | 2008-08-29 | 2015-11-18 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Ｓｍｏアンタゴニストとしての飽和二環式複素環誘導体 |
| CA2738868C (en) * | 2008-10-01 | 2017-01-17 | Novartis Ag | Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
| CA2769795C (en) | 2009-08-05 | 2020-01-07 | Infinity Pharmaceuticals, Inc. | Enzymatic transamination of cyclopamine analogs |
| JP5951600B2 (ja) | 2010-05-21 | 2016-07-13 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | キナーゼ調節のための、化合物、組成物および方法 |
| US9376447B2 (en) | 2010-09-14 | 2016-06-28 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| FR2967498B1 (fr) * | 2010-11-16 | 2015-01-02 | Centre Nat Rech Scient | Utilisation de derives de quinolinone comme outil de recherche |
| EP3238722B1 (en) | 2011-01-10 | 2019-03-13 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones |
| JP5902293B2 (ja) | 2011-04-25 | 2016-04-13 | アッシャー・サード・イニシアティブ・インコーポレイテッド | ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法 |
| US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PE20141371A1 (es) | 2011-08-29 | 2014-10-13 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos |
| US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| RU2702908C2 (ru) | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| EP2925363A4 (en) | 2012-11-29 | 2016-11-09 | Strasspharma Llc | METHOD FOR MODULATING FOLLICLE-STIMULATING HORMONACTIVITY |
| NZ629037A (en) | 2013-03-15 | 2017-04-28 | Infinity Pharmaceuticals Inc | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| KR20160013204A (ko) | 2013-05-30 | 2016-02-03 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료 |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3964507A1 (en) | 2013-10-04 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US20160244452A1 (en) | 2013-10-21 | 2016-08-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| BR112017026103B1 (pt) | 2015-06-04 | 2023-10-03 | Sol-Gel Technologies Ltd | Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| US20170231968A1 (en) | 2016-02-11 | 2017-08-17 | PellePharm, Inc. | Method for relief of and treatment of pruritus |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3474856B1 (en) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| EP4178580B1 (en) | 2020-07-09 | 2025-11-05 | Usher III Initiative, Inc. | Bf 844 for use in the treatment of cancer |
| EP4185279A4 (en) | 2020-07-24 | 2024-05-01 | Secura Bio, Inc. | TREATING CANCER WITH PI3-KINASE ISOFORM MODULATORS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6333337B1 (en) * | 1998-01-27 | 2001-12-25 | Icagen, Inc. | Potassium channel inhibitors |
| GB9807903D0 (en) * | 1998-04-14 | 1998-06-10 | Smithkline Beecham Plc | Novel compounds |
| CO5090829A1 (es) * | 1998-07-21 | 2001-10-30 | Novartis Ag | Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b. |
| US6197798B1 (en) * | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
| JP2002538167A (ja) * | 1999-03-03 | 2002-11-12 | バイオジェン インコーポレイテッド | 脂質の代謝および貯蔵を調節する方法 |
| WO2001005767A1 (en) * | 1999-07-20 | 2001-01-25 | Novartis Ag | Organic compounds |
| JP3897594B2 (ja) * | 2000-01-18 | 2007-03-28 | ノバルティス アクチエンゲゼルシャフト | ミクロソームトリグリセリド輸送タンパク質およびアポリポタンパク質分泌の阻害剤として有用なカルボキサミド |
-
2007
- 2007-04-12 BR BRPI0710723-4A patent/BRPI0710723A2/pt not_active IP Right Cessation
- 2007-04-12 US US12/297,158 patent/US20090306149A1/en not_active Abandoned
- 2007-04-12 CA CA002648196A patent/CA2648196A1/en not_active Abandoned
- 2007-04-12 MX MX2008013204A patent/MX2008013204A/es not_active Application Discontinuation
- 2007-04-12 EP EP07755420A patent/EP2010170A2/en not_active Withdrawn
- 2007-04-12 RU RU2008144805/14A patent/RU2008144805A/ru not_active Application Discontinuation
- 2007-04-12 WO PCT/US2007/009138 patent/WO2007120827A2/en not_active Ceased
- 2007-04-12 JP JP2009505499A patent/JP2009536156A/ja not_active Withdrawn
- 2007-04-12 AU AU2007238676A patent/AU2007238676A1/en not_active Abandoned
- 2007-04-12 CN CNA2007800134377A patent/CN101420949A/zh active Pending
- 2007-04-12 KR KR1020087024972A patent/KR20090006089A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| B. Johung et al. | Diffuse intrinsic pontine glioma: new pathophysiological insights and emerging therapeutic targets | |
| Jia et al. | RETRACTED ARTICLE: The silencing of LncRNA-H19 decreases chemoresistance of human glioma cells to temozolomide by suppressing epithelial-mesenchymal transition via the Wnt/β-Catenin pathway | |
| Duxbury et al. | Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells | |
| Skowron et al. | Genetic and molecular alterations across medulloblastoma subgroups | |
| CN115215808B (zh) | 用于治疗癌症的组合物和方法 | |
| Komarova et al. | Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors | |
| Sun et al. | DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation | |
| Hackl et al. | Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition | |
| JP2015520753A5 (enExample) | ||
| Ju et al. | Oncogenic KRAS promotes malignant brain tumors in zebrafish | |
| ES2743507T3 (es) | Inmunoterapia resistente a fármaco para el tratamiento de un cáncer | |
| RU2008144805A (ru) | Применение биарилкарбоксамидов в лечении заболеваний, связанных с hedgehog-путем | |
| JP2007523862A5 (enExample) | ||
| ES2978159T3 (es) | Inhibidores de factores de choque térmico (HSF) y usos de los mismos | |
| Wang et al. | STAT1 promotes KRAS colon tumor growth and susceptibility to pharmacological inhibition of translation initiation factor eIF4A | |
| JP2018062523A5 (enExample) | ||
| Cruickshanks et al. | Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1 | |
| Dean | Cancer stem cells: implications for cancer causation and therapy resistance | |
| JP2020515582A5 (enExample) | ||
| Ghassemifar et al. | MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells | |
| Liu et al. | Notch pathway deactivation sensitizes breast cancer stem cells toward chemotherapy using NIR light-responsive nanoparticles | |
| Oliver et al. | Resistance to apoptosis is increased during metastatic dissemination of colon cancer | |
| US20210137898A1 (en) | Methods to treat gliomas using a stat3 inhibitor | |
| CN107233340B (zh) | 芳香环类药物在抑制恶性黑色素瘤关键转录因子方面的应用 | |
| CN116715613A (zh) | 一种RORγ共价抑制化合物及其制备方法与应用 |